## FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

<b>STATEMENT</b>	OF CHAI	NGES IN B	ENEFICIAL	OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Instruc	tion 10.																			
1. Name and Address of Reporting Person*					2. Issuer Name and Ticker or Trading Symbol MERIT MEDICAL SYSTEMS INC MMSI								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)							
Parra Raul Jr.			_ [ ]	Director 10									wner specify							
(Last) (First) (Middle) 1600 WEST MERIT PARKWAY													J	below)	-		below)	opcony		
				3. Date of Earliest Transaction (Month/Day/Year) 11/07/2024										CFO AND TREASURER						
(Street) SOUTH JORDAL		Т	84095		4.	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)  Form filed by One Reporting Person Form filed by More than One Reporting						
(City)	(S	state)	(Zip)		-										Person				9	
		Tak	ole I - N	on-Der	ivativ	e Se	curit	ies Ac	quire	d, Di	sposed o	f, or Be	nefic	ially	Owned					
1. Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Disposed O		s Acquired (A) or Of (D) (Instr. 3, 4 and		Beneficia Owned F		es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership					
								Code	v	Amount	(A) or (D)	Price			ed ction(s) s and 4)			(Instr. 4)		
Common	Stock, No	Par Value												2,770			I	By 401(k) Plan <sup>(1)</sup>		
Common Stock, No Par Value			11/07	/2024	024			M		5,361	A	\$37	\$37.71 2		,722	D				
Common Stock, No Par Value 11/0			11/07	/2024	024		S		5,361	D	\$102	102.18 <sup>(2)</sup>		5,361		D				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	Conversion or Exercise (Month/Day/Year) Price of Derivative		3A. Deemed Execution Date, if any		tuts, calls,		umber	6. Date Exerci Expiration Date (Month/Day/Yes		sable and	or Beneficia ble securities 7. Title and Amo of Securities Underlying Derivative Secur (Instr. 3 and 4)		8. Price of Derivative Security		9. Number derivative Securities Beneficial Owned Following Reported Transactic (Instr. 4)	Ownershi Form: Direct (D) or Indirec (I) (Instr. 4		Beneficial Ownership t (Instr. 4)	
					Code	v	and (A)		Date Exercisable		Expiration Date	Title	Amou or Numb of Share	oer						
Non- qualified stock options (right to buy)	\$37.71	11/07/2024			М			5,361	02/26/20	)21 <sup>(3)</sup>	02/26/2027	Common Stock	5,36	51	\$0	5,361		D		
Non- qualified stock options (right to buy)	\$56.25								03/19/20	22 <sup>(4)</sup>	03/19/2028	Common Stock	9,68	31		9,681		D		
Non- qualified stock options (right to buy)	\$65.03								02/28/20	)23 <sup>(5)</sup>	02/28/2029	Common Stock	14,5	70		14,570	)	D		
Non- qualified stock options (right to buy)	\$70.58								02/28/20	)24 <sup>(6)</sup>	02/28/2030	Common Stock	13,5	76		13,576	5	D		

## Explanation of Responses:

- $1.\ Represents\ plan\ holdings\ as\ of\ 11/07/2024.$
- 2. The price reported in Column 4 of Table 1 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$102.17 to \$102.25, inclusive. The Reporting Person undertakes to provide to Merit Medical Systems, Inc., any security holder of Merit Medical Systems, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
- 3. Becomes exercisable in equal annual installments of 25% commencing 02/26/2021.
- $4.\ Becomes\ exercisable\ in\ equal\ annual\ installments\ of\ 25\%\ commencing\ on\ 03/19/2022.$
- 5. Becomes exercisable in equal annual installments of 25% commencing on 02/28/2023.

/s/ Brian G. Lloyd, Attorney-in-<u>Fact</u>

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.